STA Pharmaceutical is manufacturing PhoenixMDâs kinase inhibitor drug candidate for IND-enabling toxicology studies and a Phase I study in women with triple-negative breast cancer.
Original Article: STA to manufacture PhoenixMD candidate for Ph I study